The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Passenger deletions generate therapeutic vulnerabilities in cancer
Open accessAbstract
Inactivation of tumour-suppressor genes by homozygous deletion is a prototypic event in the cancer genome, yet such deletions often encompass neighbouring genes. We propose that homozygous deletions in such passenger genes can expose cancer-specific therapeutic vulnerabilities when the collaterally deleted gene is a member of a functionally redundant family of genes carrying out an essential function. The glycolytic gene enolase 1 (ENO1) in the 1p36 locus is deleted in glioblastoma (GBM), which is tolerated by the expression of ENO2. Here we show that short-hairpin-RNA-mediated silencing of ENO2 selectively inhibits growth, survival and the tumorigenic potential of ENO1-deleted GBM cells, and that the enolase inhibitor phosphonoacetohydroxamate is selectively toxic to ENO1-deleted GBM cells relative to ENO1-intact GBM cells or normal astrocytes. The principle of collateral vulnerability should be applicable to other passenger-deleted genes encoding functionally redundant essential activities and provide an effective treatment strategy for cancers containing such genomic events.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Similarly, the gene encoding enolase 1 (ENO1) is on the tumor-suppressor locus 1p36, and undergoes homozygous deletion in 1–5% of GBM cancers. Knockdown of enolase 2 (ENO2) in ENO1-null GBM cells resulted in significant inhibition of proliferation and intracranial tumorigenesis, whereas ENO1 expressing cancer cells were insensitive to ENO2 ablation.”
From Targeting Metabolism for Cancer Therapy (2017) · cites this paper as Muller et al., 2012
In the citing paper
“Furthermore, ENO1 loss results in extreme sensitivity to the pan-enolase inhibitor phosphonoacetohydroxamate (PHAH) and SF2312 (Leonard et al., 2016; Muller et al., 2012).”
From Targeting Metabolism for Cancer Therapy (2017) · cites this paper as Muller et al., 2012
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Selective killing of cancer cells by a small molecule targeting the stress response to ROS
Raj, L., Ide, T., Gurkar, A. U., Foley, M. A., Schenone, M., Li, X., Tolliday, N. J., Golub, T. R., Carr, S. A., Shamji, A. F., et al. (2011) · Nature · doi:10.1038/nature10167 · Cited by 1,040
RetractedComprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
Integrative Genomic Profiling of Human Prostate Cancer
Taylor, B. S., Schultz, N. D., Hieronymus, H., Gopalan, A., Xiao, Y., Carver, B. S., Arora, V. K., Kaushik, P., Cerami, E. G., Reva, B. A., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.05.026 · Cited by 3,713
The Genetic Landscape of a Cell
Costanzo, M., Baryshnikova, A., Bellay, J., Kim, Y., Spear, E. D., Sevier, C. S., Ding, H., Koh, J. L. Y., Toufighi, K., Mostafavi, S., et al. (2010) · Science · doi:10.1126/science.1180823 · Cited by 2,162
Glutamine addiction: a new therapeutic target in cancer
Wise, D. R., & Thompson, C. B. (2010) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2010.05.003 · Cited by 1,770
Functional genomics reveal that the serine synthesis pathway is essential in breast cancer
Possemato, R., Marks, K. M., Shaul, Y. D., Pacold, M. E., Kim, D., Birsoy, K., Sethumadhavan, S., Woo, H.-K., Jang, H. G., Jha, A. K., et al. (2011) · Nature · doi:10.1038/nature10350 · Cited by 1,683
Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies
Stommel, J. M., Kimmelman, A. C., Ying, H., Nabioullin, R., Ponugoti, A. H., Wiedemeyer, R., Stegh, A. H., Bradner, J. E., Ligon, K. L., Brennan, C., et al. (2007) · Science · doi:10.1126/science.1142946 · Cited by 938
Self-citationFull-genome RNAi profiling of early embryogenesis in Caenorhabditis elegans
Sönnichsen, B., Koski, L. B., Walsh, A., Marschall, P., Neumann, B., Brehm, M., Alleaume, A.-M., Artelt, J., Bettencourt, P. J. G., Cassin, E., et al. (2005) · Nature · doi:10.1038/nature03353 · Cited by 913
p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation
Zheng, H., Ying, H., Yan, H., Kimmelman, A. C., Hiller, D. J., Chen, A.-J., Perry, S. R., Tonon, G., Chu, G. C., Ding, Z., et al. (2008) · Nature · doi:10.1038/nature07443 · Cited by 767
Self-citationSignatures of mutation and selection in the cancer genome
Bignell, G. R., Greenman, C. D., Davies, H., Butler, A. P., Edkins, S., Andrews, J. M., Buck, G., Chen, L., Beare, D., Latimer, C., et al. (2010) · Nature · doi:10.1038/nature08768 · Cited by 707
Flagged first, then by citations
Cited by
Sorted by citations
Defining a Cancer Dependency Map
Tsherniak, A., Vazquez, F., Montgomery, P. G., Weir, B. A., Kryukov, G., Cowley, G. S., Gill, S., Harrington, W. F., Pantel, S., Krill-Burger, J. M., et al. (2017) · Cell · doi:10.1016/j.cell.2017.06.010 · Cited by 3,276
Understanding the Intersections between Metabolism and Cancer Biology
Heiden, M. G. V., & DeBerardinis, R. J. (2017) · Cell · doi:10.1016/j.cell.2016.12.039 · Cited by 2,369
Identification and characterization of essential genes in the human genome
Wang, T., Birsoy, K., Hughes, N. W., Krupczak, K. M., Post, Y., Wei, J. J., Lander, E. S., & Sabatini, D. M. (2015) · Science · doi:10.1126/science.aac7041 · Cited by 1,617
Targeting cancer metabolism in the era of precision oncology
Stine, Z. E., Schug, Z. T., Salvino, J. M., & Dang, C. V. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00339-6 · Cited by 1,189
An inhibitor of oxidative phosphorylation exploits cancer vulnerability
Molina, J. R., Sun, Y., Protopopova, M., Gera, S., Bandi, M., Bristow, C., McAfoos, T., Morlacchi, P., Ackroyd, J., Agip, A.-N. A., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0052-4 · Cited by 928
Self-citationTargeting Metabolism for Cancer Therapy
Luengo, A., Gui, D. Y., & Vander Heiden, M. G. (2017) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.08.028 · Cited by 971
McDonald, E. R., de Weck, A., Schlabach, M. R., Billy, E., Mavrakis, K. J., Hoffman, G. R., Belur, D., Castelletti, D., Frias, E., Gampa, K., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.005 · Cited by 658
Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5
Mavrakis, K. J., McDonald, E. R., Schlabach, M. R., Billy, E., Hoffman, G. R., deWeck, A., Ruddy, D. A., Venkatesan, K., Yu, J., McAllister, G., et al. (2016) · Science · doi:10.1126/science.aad5944 · Cited by 607
Neuron-Specific Enolase as a Biomarker: Biochemical and Clinical Aspects
Isgrò, M. A., Bottoni, P., & Scatena, R. (2015) · Advances in experimental medicine and biology · doi:10.1007/978-94-017-7215-0_9 · Cited by 600
MTAP deletions in cancer create vulnerability to targeting of the MAT2A/PRMT5/RIOK1 axis
Marjon, K., Cameron, M. J., Quang, P., Clasquin, M. F., Mandley, E., Kunii, K., McVay, M., Choe, S., Kernytsky, A., Gross, S., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.03.043 · Cited by 485
Synthetic lethality as an engine for cancer drug target discovery
Huang, A., Garraway, L. A., Ashworth, A., & Weber, B. L. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0046-z · Cited by 490
Daemen, A., Peterson, D., Sahu, N., McCord, R., Du, X., Liu, B., Kowanetz, K., Hong, R., Moffat, J., Gao, M., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1501605112 · Cited by 398
Synthetic lethal therapies for cancer: what’s next after PARP inhibitors?
Ashworth, A., & Lord, C. J. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0055-6 · Cited by 434
Garofano, L., Migliozzi, S., Oh, Y. T., D’Angelo, F., Najac, R. D., Ko, A., Frangaj, B., Caruso, F. P., Yu, K., Yuan, J., et al. (2021) · Nature Cancer · doi:10.1038/s43018-020-00159-4 · Cited by 380
McCubrey, J. A., Steelman, L. S., Chappell, W. H., Abrams, S. L., Montalto, G., Cervello, M., Nicoletti, F., Fagone, P., Malaponte, G., Mazzarino, M. C., et al. (2012) · Oncotarget · doi:10.18632/oncotarget.652 · Cited by 318
Oike, T., Ogiwara, H., Tominaga, Y., Ito, K., Ando, O., Tsuta, K., Mizukami, T., Shimada, Y., Isomura, H., Komachi, M., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4593 · Cited by 305
Gopal, R. K., Kübler, K., Calvo, S. E., Polak, P. P., Livitz, D. G., Rosebrock, D., Sadow, P. M., Campbell, B., Donovan, S. E., Amin, S., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.06.013 · Cited by 271
Genomic deletion of malic enzyme 2 confers collateral lethality in pancreatic cancer
Dey, P., Baddour, J., Muller, F., Wu, C. C., Wang, H., Liao, W.-T., Lan, Z., Chen, A., Gutschner, T., Kang, Y., et al. (2017) · Nature · doi:10.1038/nature21052 · Cited by 264
Self-citationTP53 loss creates therapeutic vulnerability in colorectal cancer
Liu, Y., Zhang, X., Han, C., Wan, G., Huang, X., Ivan, C., Jiang, D., Rodriguez‐Aguayo, C., Lopez‐Berestein, G., Rao, P. H., et al. (2015) · Nature · doi:10.1038/nature14418 · Cited by 243
Aurora A Kinase Inhibition Is Synthetic Lethal with Loss of the RB1 Tumor Suppressor Gene
Gong, X., Du, J., Parsons, S. H., Merzoug, F. F., Webster, Y., Iversen, P. W., Chio, L.-C., Horn, R. D. V., Lin, X., Blosser, W. D., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0469 · Cited by 243
Metabolic Reprogramming of Cancer Cells during Tumor Progression and Metastasis
Ohshima, K., & Morii, E. (2021) · Metabolites · doi:10.3390/metabo11010028 · Cited by 236
Song, Y., Luo, Q., Long, H., Hu, Z. M., Que, T., Zhang, X., Li, Z., Wang, G., Liu, Y., Liu, Z., et al. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-65 · Cited by 221
Synthetic essentiality of chromatin remodelling factor CHD1 in PTEN-deficient cancer
Zhao, D., Lü, X., Wang, G., Lan, Z., Liao, W., Li, J., Liang, X., Chen, J., Shah, S. R., Shang, X., et al. (2017) · Nature · doi:10.1038/nature21357 · Cited by 227
Self-citationAn expanded universe of cancer targets
Hahn, W. C., Bader, J. S., Braun, T. P., Califano, A., Clemons, P. A., Druker, B. J., Ewald, A. J., Fu, H., Jagu, S., Kemp, C. J., et al. (2021) · Cell · doi:10.1016/j.cell.2021.02.020 · Cited by 213
NEAT1 is essential for metabolic changes that promote breast cancer growth and metastasis
Park, M. K., Zhang, L., Min, K., Cho, J.-H., Yeh, C., Moon, H., Hormaechea‐Agulla, D., Mun, H., Ko, S., Lee, J. W., et al. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.11.011 · Cited by 216
Self-citationSynthetic Lethality in Cancer Therapeutics: The Next Generation
Setton, J. S., Zinda, M. J., Riaz, N., Durocher, D., Zimmermann, M., Koehler, M. T., Reis-Filho, J. S., & Powell, S. N. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1503 · Cited by 214
Huang, C. K., Sun, Y., Lv, L., & Ping, Y. (2022) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2021.12.026 · Cited by 208
ENO1 suppresses cancer cell ferroptosis by degrading the mRNA of iron regulatory protein 1
Zhang, T., Sun, L., Hao, Y., Suo, C., Shen, S., Wei, H., Ma, W., Zhang, P., Wang, T., Gu, X., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00299-1 · Cited by 209
Therapeutic targeting of tumor suppressor genes
Morris, L. G. T., & Chan, T. A.-T. (2014) · Cancer · doi:10.1002/cncr.29140 · Cited by 209
Cancer systems biology: embracing complexity to develop better anticancer therapeutic strategies
Du, W., & Elemento, O. (2014) · Oncogene · doi:10.1038/onc.2014.291 · Cited by 185
Molenaar, R. J., Radivoyevitch, T., Maciejewski, J. P., Noorden, C. J. F. V., & Bleeker, F. E. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.05.004 · Cited by 186
Munck, C., Gumpert, H., Wallin, A. I. N., Wang, H. H., & Sommer, M. O. A. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009940 · Cited by 176
The landscape of gene mutations in cirrhosis and hepatocellular carcinoma
Müller, M., Bird, T. G., & Nault, J. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.01.019 · Cited by 182
Kim, H. S., Mendiratta, S., Kim, J., Pecot, C. V., Larsen, J. E., Zubovych, I., Seo, B. Y., Kim, J., Eskiocak, B., Chung, H., et al. (2013) · Cell · doi:10.1016/j.cell.2013.09.041 · Cited by 172
Li, Z., Meng, X., Wu, P., Zha, C., Han, B., Li, L., Sun, N., Qi, T., Qin, J., Zhang, Y., et al. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-0258 · Cited by 168
Impact of cancer metabolism on therapy resistance – Clinical implications
Gonçalves, A. C., Richiardone, E., Jorge, J., Polónia, B. R. G., Xavier, C. P. R., Salaroglio, I. C., Riganti, C., Vasconcelos, M. H., Corbet, C., & Sarmento‐Ribeiro, A. B. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100797 · Cited by 176
ILF2 Is a Regulator of RNA Splicing and DNA Damage Response in 1q21-Amplified Multiple Myeloma
Marchesini, M., Ogoti, Y., Fiorini, E., Samur, A. A., Nezi, L., D’Anca, M., Storti, P., Samur, M., Gañán‐Gómez, I., Fulciniti, M. T., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.05.011 · Cited by 160
Self-citationGBM's multifaceted landscape: highlighting regional and microenvironmental heterogeneity
Vartanian, A., Singh, S. K., Agnihotri, S., Jalali, S., Burrell, K. E., Aldape, K., & Zadeh, G. M. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou035 · Cited by 158
Capello, M., Borgogno, S. F., Riganti, C., Chattaragada, M. S., Principe, M., Roux, C., Zhou, W., Petricoin, E. F., Cappello, P., & Novelli, F. (2015) · Oncotarget · doi:10.18632/oncotarget.6798 · Cited by 153
Antonysamy, S., Pustilnik, A., Manglicmot, D., Froning, K., Weichert, K., & Wasserman, S. (2018) · Worldwide Protein Data Bank · doi:10.2210/pdb6c2r/pdb · Cited by 148
Dai, J., Zhou, Q., Chen, J., Rexius‐Hall, M. L., Rehman, J., & Zhou, G. (2018) · Nature Communications · doi:10.1038/s41467-018-06376-x · Cited by 149
Metabolic Abnormalities in Glioblastoma and Metabolic Strategies to Overcome Treatment Resistance
Zhou, W., & Wahl, D. R. (2019) · Cancers · doi:10.3390/cancers11091231 · Cited by 152
Exploiting Metabolic Vulnerabilities of Cancer with Precision and Accuracy
Wolpaw, A. J., & Dang, C. V. (2017) · Trends in Cell Biology · doi:10.1016/j.tcb.2017.11.006 · Cited by 151
The Conundrum of Genetic “Drivers” in Benign Conditions
Kato, S., Lippman, S. M., Flaherty, K. T., & Kurzrock, R. (2016) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djw036 · Cited by 149
Targeting glucose metabolism enzymes in cancer treatment: current and emerging strategies
Zhang, Y., Li, Q., Huang, Z., Li, B., Nice, E. C., Huang, C., Wei, L., & Zou, B. (2022) · Cancers · doi:10.3390/cancers14194568 · Cited by 144
Collateral lethality: a new therapeutic strategy in oncology
Muller, F. L., Aquilanti, E. A., & DePinho, R. A. (2015) · Trends in Cancer · doi:10.1016/j.trecan.2015.10.002 · Cited by 132
Self-citationME1 Regulates NADPH Homeostasis to Promote Gastric Cancer Growth and Metastasis
Lu, Y., Ju, H., Liu, Z., Chen, D.-L., Wang, Y., Zhao, Q., Wu, Q.-N., Zeng, Z.-L., Qiu, H.-B., Hu, P.-S., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3155 · Cited by 143
Self-citationEnolase 1, a Moonlighting Protein, as a Potential Target for Cancer Treatment
Qiao, G., Wu, A., Chen, X., Tian, Y., & Lin, X. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.63556 · Cited by 139
Morandi, A., Taddei, M. L., Chiarugi, P., & Giannoni, E. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00040 · Cited by 146
Riboregulation of Enolase 1 activity controls glycolysis and embryonic stem cell differentiation
Huppertz, I., Perez-Perri, J. I., Mantas, P., Sekaran, T., Schwarzl, T., Russo, F., Ferring–Appel, D., Koskova, Z., Dimitrova-Paternoga, L., Kafkia, E., et al. (2022) · Molecular Cell · doi:10.1016/j.molcel.2022.05.019 · Cited by 140
Comprehensive Analysis of Glycolytic Enzymes as Therapeutic Targets in the Treatment of Glioblastoma
Sanzey, M., Rahim, S. A. A., Oudin, A., Dirkse, A., Kaoma, T., Vallar, L., Herold‐Mende, C. C., Bjerkvig, R., Golebiewska, A., & Niclou, S. P. (2015) · PLoS ONE · doi:10.1371/journal.pone.0123544 · Cited by 130
Zheng, Y., Wu, C., Yang, J., Zhao, Y., Jia, H., Xue, M., Xu, D., Yang, F., Fu, D., Wang, C., et al. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0146-6 · Cited by 120
Self-citationThe Damaging Effect of Passenger Mutations on Cancer Progression
McFarland, C. D., Yaglom, J. A., Wojtkowiak, J. W., Scott, J. G., Morse, D. L., Sherman, M. Y., & Mirny, L. A. (2017) · Cancer Research · doi:10.1158/0008-5472.can-15-3283-t · Cited by 126
Niu, Y., Lin, Z., Wan, A., Sun, L., Yan, S., Liang, H., Zhan, S., Chen, D., Bu, X., Liu, P., et al. (2021) · Hepatology · doi:10.1002/hep.31846 · Cited by 115
Combination therapeutics in complex diseases
He, B., Lu, C., Zheng, G., He, X., Wang, M., Chen, G., Zhang, G., & Lu, A. (2016) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12930 · Cited by 112
Lin, K., Xie, A., Rutter, J. C., Ahn, Y.-R., Lloyd-Cowden, J. M., Nichols, A., Soderquist, R. S., Koves, T. R., Muoio, D. M., MacIver, N. J., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.01.011 · Cited by 110
Targeting tumor suppressor genes for cancer therapy
Liu, Y., Hu, X., Han, C., Wang, L., Zhang, X., He, X., & Lu, X. (2015) · BioEssays · doi:10.1002/bies.201500093 · Cited by 112
Gladyshev, V. N. (2013) · Trends in Genetics · doi:10.1016/j.tig.2013.05.004 · Cited by 111
Nuclear BK channels regulate gene expression via the control of nuclear calcium signaling
Li, B., Jie, W., Huang, L., Wei, P., Li, S., Luo, Z.-Y., Friedman, A. K., Meredith, A. L., Han, M., Zhu, X., et al. (2014) · Nature Neuroscience · doi:10.1038/nn.3744 · Cited by 108
Ajore, R., Raiser, D. M., McConkey, M. E., Jöud, M., Boidol, B., Mar, B. G., Saksena, G., Weinstock, D. M., Armstrong, S. A., Ellis, S. R., et al. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201606660 · Cited by 104
Nichols, C. A., Gibson, W. J., Brown, M. S., Kosmicki, J. A., Busanovich, J. P., Wei, H. Y., Urbanski, L. M., Currimjee, N., Berger, A. C., Gao, G. F., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16399-y · Cited by 107
Barresi, V., Salinaro, A. T., Spampinato, G., Musso, N., Castorina, S., Rizzarelli, E., & Condorelli, D. F. (2016) · FEBS Open Bio · doi:10.1002/2211-5463.12060 · Cited by 105
Cancer genome-sequencing study design
Mwenifumbo, J. C., & Marra, M. A. (2013) · Nature Reviews Genetics · doi:10.1038/nrg3445 · Cited by 104
Extracellular assembly and activation principles of oncogenic class III receptor tyrosine kinases
Verstraete, K., & Savvides, S. N. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3371 · Cited by 102
SF2312 is a natural phosphonate inhibitor of enolase
Leonard, P. G., Satani, N., Maxwell, D., Lin, Y.-H., Hammoudi, N., Peng, Z., Pisaneschi, F., Link, T. M., Lee, G. R., Sun, D., et al. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.2195 · Cited by 96
Self-citationZhao, D., Badur, M. G., Luebeck, J., Magaña, J. H., Birmingham, A., Šášik, R., Ahn, C. S., Ideker, T., Metallo, C. M., & Mali, P. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.01.017 · Cited by 96
Cancer-associated mutations in endometriosis: shedding light on the pathogenesis and pathophysiology
Guo, S.-W. (2020) · Human Reproduction Update · doi:10.1093/humupd/dmz047 · Cited by 96
Vidaurre, S., Fitzpatrick, C. J., Burzio, V. A., Briones, M., Villota, C., Villegas, J., Echenique, J., Oliveira-Cruz, L., Araya, M., Borgna, V., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.558841 · Cited by 94
Paralog buffering contributes to the variable essentiality of genes in cancer cell lines
De Kegel, B., & Ryan, C. J. (2019) · PLOS Genetics · doi:10.1371/journal.pgen.1008466 · Cited by 92
An enolase inhibitor for the targeted treatment of ENO1-deleted cancers
Lin, Y.-H., Satani, N., Hammoudi, N., Yan, V. C., Barekatain, Y., Khadka, S., Ackroyd, J. J., Georgiou, D. K., Pham, C.-D., Arthur, K., et al. (2020) · Nature Metabolism · doi:10.1038/s42255-020-00313-3 · Cited by 92
Self-citationAn update on therapeutic opportunities offered by cancer glycolytic metabolism
Granchi, C., Fancelli, D., & Minutolo, F. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.09.041 · Cited by 94
Alpha-Enolase i ENO1 i a potential target in novel immunotherapies
Novelli, F. (2016) · Frontiers in bioscience · doi:10.2741/4526 · Cited by 91
The regulatory roles and clinical significance of glycolysis in tumor
Qiao, Q., Hu, S., & Wang, X. (2024) · 癌症：英文版 · doi:10.1002/cac2.12549 · Cited by 90
Lineweaver, C. H., Davies, P. C. W., & Vincent, M. D. (2014) · BioEssays · doi:10.1002/bies.201400070 · Cited by 89
Translating insights into tumor evolution to clinical practice: promises and challenges
Fittall, M. W., & Loo, P. V. (2019) · Genome Medicine · doi:10.1186/s13073-019-0632-z · Cited by 91
William, W. N., Zhao, X., Bianchi, J. J., Lin, H. Y., Cheng, P., Lee, J. J., Carter, H. K., Alexandrov, L. B., Abraham, J. P., Spetzler, D. B., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2022655118 · Cited by 84
Self-citationSyrosingopine sensitizes cancer cells to killing by metformin
Benjamin, D., Colombi, M., Hindupur, S. K., Betz, C., Lane, H. A., El‐Shemerly, M., Lu, M., Quagliata, L., Terracciano, L., Moes, S., et al. (2016) · Science Advances · doi:10.1126/sciadv.1601756 · Cited by 89
Recurrent patterns of DNA copy number alterations in tumors reflect metabolic selection pressures
Graham, N. A., Minasyan, A., Lomova, A., Cass, A. A., Balanis, N. G., Friedman, M., Chan, S. T., Zhao, S. R., Delgado, A., Go, J. L., et al. (2017) · Molecular Systems Biology · doi:10.15252/msb.20167159 · Cited by 78
DNA Mutations May Not Be the Cause of Cancer
Adjiri, A. (2017) · Oncology and Therapy · doi:10.1007/s40487-017-0047-1 · Cited by 76
Metabolic heterogeneity and adaptability in brain tumors
Badr, C. E., Silver, D. J., Siebzehnrübl, F. A., & Deleyrolle, L. P. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03569-w · Cited by 77
Reactive metabolite production is a targetable liability of glycolytic metabolism in lung cancer
Luengo, A., Abbott, K. L., Davidson, S. M., Hosios, A. M., Faubert, B., Chan, S. H., Freinkman, E., Zacharias, L. G., Mathews, T. P., Clish, C. B., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-13419-4 · Cited by 75
Oncogenic and Tumor-Suppressive Functions of NOTCH Signaling in Glioma
Parmigiani, E., Taylor, V., & Giachino, C. (2020) · Cells · doi:10.3390/cells9102304 · Cited by 74
Focal chromosomal copy number aberrations in cancer—Needles in a genome haystack
Krijgsman, O., Carvalho, B. G., Meijer, G. A., Steenbergen, R. D. M., & Ylstra, B. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2014.08.001 · Cited by 73
Linn, P., Kohno, S., Sheng, J., Kulathunga, N., Yu, H., Zhang, Z., Voon, D. C., Watanabe, Y., & Takahashi, C. (2021) · Cancers · doi:10.3390/cancers13153737 · Cited by 70
Biological Relevance and Therapeutic Potential of the Hypusine Modification System
Pällmann, N., Braig, M., Sievert, H., Preukschas, M., Hermans‐Borgmeyer, I., Schweizer, M., Nagel, C., Neumann, M., Wild, P. J., Haralambieva, E., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.664490 · Cited by 68
Comprehensive prediction of robust synthetic lethality between paralog pairs in cancer cell lines
Kegel, B. D., Quinn, N., Thompson, N., Adams, D. J., & Ryan, C. J. (2021) · Cell Systems · doi:10.1016/j.cels.2021.08.006 · Cited by 67
The Contributions of HIF-Target Genes to Tumor Growth in RCC
Zhang, T., Niu, X., Liao, L., Cho, E.-A., & Yang, H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0080544 · Cited by 68
Differential Aspartate Usage Identifies a Subset of Cancer Cells Particularly Dependent on OGDH
Allen, E. L., Ulanet, D., Pirman, D. A., Mahoney, C. E., Coco, J., Si, Y., Chen, Y., Huang, L., Ren, J., Choe, S. E., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.09.052 · Cited by 69
Determinants of nutrient limitation in cancer
Sullivan, M. R., & Heiden, M. G. V. (2019) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409238.2019.1611733 · Cited by 70
Fang, J., Barker, B., Bolanos, L. C., Liu, X., Jerez, A., Makishima, H., Christie, S., Chen, X., Rao, D. S., Grimes, H. L., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.07.062 · Cited by 65
Deng, T., Shen, P., Li, A., Zhang, Z., Yang, H., Deng, X., Peng, X., Hu, Z., Tang, Z., Liu, J., et al. (2021) · Theranostics · doi:10.7150/thno.54961 · Cited by 65
Gonçalves, E., Behan, F. M., Louzada, S., Arnol, D., Stronach, E. A., Yang, F., Yusa, K., Stegle, O., Iorio, F., & Garnett, M. J. (2019) · Genome biology · doi:10.1186/s13059-019-1637-z · Cited by 60
Clinical Development of Molecular Targeted Therapy in Head and Neck Squamous Cell Carcinoma
Gougis, P., Moreau-Bachelard, C., Kamal, M. T., Gan, H. K., Borcoman, É., Torossian, N., Bièche, I., & Tourneau, C. L. (2019) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkz055 · Cited by 63
Neggers, J. E., Paolella, B. R., Asfaw, A., Rothberg, M. V., Skipper, T. A., Yang, A., Kalekar, R. L., Krill-Burger, J. M., Dharia, N. V., Kugener, G., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108493 · Cited by 62
An allosteric PGAM1 inhibitor effectively suppresses pancreatic ductal adenocarcinoma
Wen, C., Huang, K., Jiang, L.-L., Lu, X., Dai, Y., Shi, M.-M., Tang, X.-M., Wang, Q., Zhang, X., Wang, P., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1914557116 · Cited by 61
Therapeutic targeting of PGBD5-induced DNA repair dependency in pediatric solid tumors
Henssen, A. G., Reed, C., Jiang, E., García, H. D., von Stebut, J., MacArthur, I. C., Hundsdoerfer, P., Kim, J. H., de Stanchina, E., Kuwahara, Y., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aam9078 · Cited by 60
Glioblastoma Metabolism: Insights and Therapeutic Strategies
Bernhard, C., Reita, D., Martin, S., Entz‐Werlé, N., & Dontenwill, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119137 · Cited by 66
Cancer driver mutations in endometriosis: Variations on the major theme of fibrogenesis
Guo, S. (2018) · Reproductive Medicine and Biology · doi:10.1002/rmb2.12221 · Cited by 58
Barekatain, Y., Ackroyd, J. J., Yan, V. C., Khadka, S., Wang, L., Chen, K., Poral, A. H., Tran, T. T., Georgiou, D. K., Arthur, K., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24240-3 · Cited by 63
Targeting synthetic lethal paralogs in cancer
Ryan, C. J., Mehta, I., Kebabci, N., & Adams, D. J. (2023) · Trends in cancer · doi:10.1016/j.trecan.2023.02.002 · Cited by 59
Metadata
- Authors
- Muller, F. L., Colla, S., Aquilanti, E., Manzo, V. E., Genovese, G., Lee, J., Eisenson, D., Narurkar, R., Deng, P., Nezi, L., Lee, M. A., Hu, B., Hu, J., Sahin, E., Ong, D., Fletcher-Sananikone, E., Ho, D., Kwong, L., Brennan, C., Wang, Y. A., Chin, L., & DePinho, R. A.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Dana-Farber Cancer Institute (US)
- Harvard University (US)
- Memorial Sloan Kettering Cancer Center (US)
- Corresponding author
- DePinho, Ronald A.
- ORCID
- Venue
- Nature
- Published
- 2012-08-15
- Volume
- 488
- Issue
- 7411
- Pages
- 337-342
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3712624
- OpenAlex
- W1982318323
- Cited by
- 339
- References
- 38
- Citations by year
- 2026: 12 · 2025: 20 · 2024: 20 · 2023: 20 · 2022: 32 · 2021: 34 · 2020: 32 · 2019: 32 · 2018: 20 · 2017: 27 · 2016: 18 · 2015: 19 · 2014: 33 · 2013: 14 · 2012: 6
- FWCI
- 7.62
- Type
- journal article
- Language
- en
- Update notices
- correction (2015-07-08)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Howard Hughes Medical Institute (57006984)
- National Eye Institute (R01EY020641)
- National Cancer Institute (P01 CA 95616, T32CA009361, P01CA095616)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Keywords
- alpha-enolase, neuron-specific enolase, enolase, 1p36 deletion, glioblastoma, housekeeping genes, glycolysis, RNA interference, tumor suppressor, cancer therapy
- MeSH terms
- Animals, Antineoplastic Agents, Brain Neoplasms, Chromosomes, Human, Pair 1, DNA-Binding Proteins, Enzyme Inhibitors, Glioblastoma, Homozygote, Humans, Hydroxamic Acids, Neoplasm Transplantation, Phosphonoacetic Acid, Phosphopyruvate Hydratase, Biomarkers, Tumor, Gene Expression Regulation, Neoplastic, Genes, Tumor Suppressor, Sequence Deletion, Genes, Essential, Tumor Suppressor Proteins, RNA, Small Interfering, Cell Line, Tumor, Cell Proliferation, Mice, Gene Knockdown Techniques, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
